Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has received approval for its Acuity Spiral left ventricular lead for use with cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers, both of which treat heart failure.
Subscribe to our email newsletter
The Acuity features a spiral fixation design and small lead tip profile (4.1 French tapering to 2.6 French) for placement of the lead in veins of varying sizes, including difficult-to-access veins. A lead is an insulated wire that carries the heart signal to the implanted device and delivers energy from the device to the heart.
Boston Scientific is also conducting a prospective, multi-center trial designed to collect and analyze real-world performance data for the Acuity Spiral lead. The study will enroll approximately 1,700 patients in up to 125 centers. Patients will be followed over a period of five years and will be enrolled on Boston Scientific’s Latitude Patient Management system, enabling wireless remote management of patients.
John Hummel, principal investigator of the Acuity Spiral US clinical trial, said: “In the US clinical trial, the Acuity Spiral fixation design provided excellent stability after implant. Acuity Spiral has the smallest left ventricular lead tip profile in the industry, offering greater flexibility to place the lead in veins I may have avoided in the past.”